Biosyngen

Executive Summary

Biosyngen is a Singapore-based immuno-oncology company founded in 2016, focused on developing next-generation cell therapies for solid tumors, including nasopharyngeal, lung, liver, and gastrointestinal cancers. The company leverages proprietary technologies such as the M-CEL manufacturing platform, which enables accelerated production cycles, and the SUPER-T safety-optimization technology, designed to reduce off-target effects while maintaining high-affinity tumor recognition. Biosyngen’s pipeline includes CAR-T, TCR-T, and TIL programs, with its lead candidate targeting nasopharyngeal carcinoma currently in Phase 2 clinical development. By addressing key challenges in solid tumor treatment—such as tumor heterogeneity and immunosuppressive microenvironments—Biosyngen aims to deliver first-in-class therapies with improved efficacy and safety profiles. The company operates with a lean structure and has demonstrated progress in early-stage trials, positioning itself as a promising player in the competitive cell therapy landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 interim data readout for lead CAR-T candidate in nasopharyngeal carcinoma60% success
• Q2 2026FDA Orphan Drug Designation for lead TCR-T program80% success
• TBDPotential strategic partnership or licensing deal for M-CEL manufacturing platform50% success